ArticleJournal of the American Chemical Society2015
A Manganese Alternative to Gadolinium for MRI Contrast.
Article in Journal of the American Chemical Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
113 citing papers in PubMed, 329 citations in OpenAlex.
- Magnetic resonance imaging.Science advances · 2026Review
- Ultrasmall Ag₂Se@Mn quantum dots enable dual-modal imaging-guided early detection and antioxidant therapy of acute kidney injury.Mikrochimica acta · 2026Article
- Manganese-Doped Carbon Nanodots as Next-Generation MRI and Fluorescence Imaging Agents.ACS nano · 2026Article
- Asymmetrically Coordinated Dual-Atom Manganese Contrast Agents Enabling High-Efficiency T1 Enhanced MRI for Precise Tumor Visualization.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Pyridinophane Ligands: An Attractive Chelator Platform for Mn-Based Imaging Agents.Journal of medicinal chemistry · 2026Article
- Zwitterionic Mn(III)-Tetraphenyl Porphyrins: Water-Soluble MRI Contrast Agents with High Relaxivity.ChemMedChem · 2026Article
- Manganese-Templated Nontrivial Structures for MRI and Therapy.Journal of the American Chemical Society · 2026Article
- Quality Assurance Strategies for Brain State Characterization by MEMRI.bioRxiv : the preprint server for biology · 2026Article
- Gadolinium-based contrast agents in pediatric MRI: renal safety, risk mitigation, and emerging alternatives.Pediatric radiology · 2026Review
- Investigating Cu(II) Complexes for MRI: A Comprehensive Approach Using EPR, Relaxometry, and Computational Modeling.Inorganic chemistry · 2026Article
- Tumor Microenvironment-Responsive Nanomedicine: Monitoring and Modulating the Tumor Microenvironment for Precision Cancer Therapy.International journal of nanomedicine · 2026Review
- Chemical Tools to Characterize the Coordination Chemistry of Radionuclides for Radiopharmaceutical Applications.Chemical reviews · 2025Review
- MnChemistry (Weinheim an der Bergstrasse, Germany) · 2025Article
- Superhydrophilic FeAngewandte Chemie (International ed. in English) · 2025Article
- Removal of Toxic Metabolites-Chelation: Manganese Disorders.Journal of inherited metabolic disease · 2025Review
- Radiolabeled Nanogels: From Multimodality Imaging to Combination Therapy of Cancer.Small science · 2025Review
- Design of Mn(1,4-DO2A) derivatives as stable and inert contrast agents for magnetic resonance imaging.Communications chemistry · 2025Article
- Artificial intelligence-assisted magnetic resonance lymphography for evaluation of micro- and macro-sentinel lymph node metastasis in breast cancer.Materials today. Bio · 2025Article
- Manganese-based type I collagen-targeting MRI probe for in vivo imaging of liver fibrosis.Npj imaging · 2025Article
- Water-Soluble Mn(III)-Porphyrins with High Relaxivity and Photosensitization.Chemical & biomedical imaging · 2025Article
53 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI) are routinely used to diagnose soft tissue and vascular abnormalities. However, safety concerns limit the use of iodinated and gadolinium (Gd)-based CT and MRI contrast media in renally compromised patients. With an estimated 14% of the US population suffering from chronic kidney disease (CKD), contrast media compatible with renal impairment is sorely needed. We present the new manganese(II) complex [Mn(PyC3A)(H2O)](-) as a Gd alternative. [Mn(PyC3A)(H2O)](-) is among the most stable Mn(II) complexes at pH 7.4 (log KML = 11.40). In the presence of 25 mol equiv of Zn at pH 6.0, 37 °C, [Mn(PyC3A)(H2O)](-) is 20-fold more resistant to dissociation than [Gd(DTPA)(H2O)](2-). Relaxivity of [Mn(PyC3A)(H2O)](-) in blood plasma is comparable to commercial Gd contrast agents. Biodistribution analysis confirms that [Mn(PyC3A)(H2O)](-) clears via a mixed renal/hepatobiliary pathway with >99% elimination by 24 h. [Mn(PyC3A)(H2O)](-) was modified to form a bifunctional chelator and 4 chelates were conjugated to a fibrin-specific peptide to give Mn-FBP. Mn-FBP binds the soluble fibrin fragment DD(E) with Kd = 110 nM. Per Mn relaxivity of Mn-FBP is 4-fold greater than [Mn(PyC3A)(H2O)](-) and increases 60% in the presence of fibrin, consistent with binding. Mn-FBP provided equivalent thrombus enhancement to the state of the art Gd analogue, EP-2104R, in a rat model of arterial thrombosis. Mn metabolite analysis reveals no evidence of dechelation and the probe was >99% eliminated after 24 h. [Mn(PyC3A)(H2O)](-) is a lead development candidate for an imaging probe that is compatible with renally compromised patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.